VAXX - Vaxxinity, Inc. Stock Price and Quote

VAXX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.61	Insider Own	47.00%	Shs Outstand	126.04M	Perf Week	4.31%
Market Cap	267.18M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	-1.45%	Shs Float	49.46M	Perf Month	-9.17%
Income	-102.60M	PEG	-	EPS next Q	-0.16	Inst Own	23.40%	Short Float / Ratio	3.82% / 5.56	Perf Quarter	57.97%
Sales	-0.00M	P/S	-	EPS this Y	-241.60%	Inst Trans	0.49%	Short Interest	1.89M	Perf Half Y	7.39%
Book/sh	0.64	P/B	3.41	EPS next Y	-	ROA	-	Target Price	13.50	Perf Year	-47.60%
Cash/sh	0.81	P/C	2.70	EPS next 5Y	-	ROE	-	52W Range	1.24 - 8.35	Perf YTD	55.71%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-73.89%	Beta	-
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	-	Gross Margin	-	52W Low	75.81%	ATR	0.23
Employees	89	Current Ratio	3.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.49	Volatility	6.89% 10.36%
Optionable	No	Debt/Eq	0.13	EPS Q/Q	65.50%	Profit Margin	-	Rel Volume	0.00	Prev Close	2.18
Shortable	Yes	LT Debt/Eq	0.12	Earnings	-	Payout	-	Avg Volume	339.61K	Price	2.18
Recom	1.70	SMA20	0.20%	SMA50	-18.62%	SMA200	4.64%	Volume	0	Change	0.00%

Apr-27-22

Initiated

Evercore ISI

In-line

Mar-28-23 08:00AM	Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April GlobeNewswire
Mar-27-23 07:50AM	Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates GlobeNewswire
Mar-21-23 08:00AM	Vaxxinity Joins TransCelerate Research and Development Consortium GlobeNewswire +16.18%
Mar-20-23 08:00AM	Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia GlobeNewswire
Mar-02-23 08:00AM	Vaxxinity to Present at Upcoming March Scientific and Medical Conferences GlobeNewswire
07:40PM	Loading…
Feb-01-23 07:40PM	Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida GlobeNewswire
Jan-19-23 02:04PM	Why Shares of Vaxxinity Jumped This Week Motley Fool +5.49%
Jan-05-23 08:00AM	Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-22 07:35AM	Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX) Simply Wall St.
Dec-02-22 08:00AM	Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612 GlobeNewswire -14.29%
05:30AM	Why Shares of Vaxxinity Soared This Week Motley Fool
Nov-10-22 07:30AM	Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-22 08:00AM	Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022 GlobeNewswire
Nov-01-22 09:00AM	Vaxxinity to Present at Upcoming Investor Conferences in November GlobeNewswire +6.06%
Oct-30-22 10:27AM	Vaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21% Simply Wall St.
08:00AM	Loading…
Oct-24-22 08:00AM	Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia GlobeNewswire -6.58%
Sep-19-22 09:00AM	Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders Simply Wall St.
Sep-13-22 08:00AM	Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine GlobeNewswire
Sep-12-22 08:00AM	Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK) GlobeNewswire
Sep-01-22 08:00AM	Vaxxinity to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-15-22 04:39PM	UK approves COVID vaccine that targets Omicron subvariants Yahoo Finance Video
Aug-12-22 04:19PM	Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity Yahoo Finance
Aug-11-22 08:00AM	Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates GlobeNewswire
Aug-04-22 07:00AM	Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference GlobeNewswire +7.05%
Aug-02-22 01:43PM	Vaxxinity's Vaccine Candidate Shows Durable Cholesterol Lowering Activity In Animal Models Benzinga +14.58%
08:00AM	Vaxxinitys Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates GlobeNewswire
Aug-01-22 08:00AM	Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC) GlobeNewswire +9.71%
Jul-25-22 11:57AM	Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines GlobeNewswire
Jun-02-22 07:00AM	Vaxxinity to Participate at the Jefferies Healthcare Conference GlobeNewswire
May-12-22 09:31AM	What Percentage Of Vaxxinity, Inc. (NASDAQ:VAXX) Shares Do Insiders Own? Simply Wall St.
07:42AM	Loading…
May-09-22 07:42AM	Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates GlobeNewswire
May-05-22 07:00AM	Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference GlobeNewswire -17.28%
May-02-22 08:00AM	Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimers Disease GlobeNewswire
Apr-28-22 08:00AM	Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinsons Disease GlobeNewswire
Apr-12-22 08:43AM	Insiders who bought stock earlier this year lose -US$216k as Vaxxinity, Inc. (NASDAQ:VAXX) drops to US$505m Simply Wall St.
Apr-07-22 08:14AM	Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial Benzinga
Apr-06-22 04:43PM	CEPI to co-fund Vaxxinitys pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants GlobeNewswire -5.02%
Mar-28-22 08:00AM	Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster GlobeNewswire
Mar-24-22 04:05PM	Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates GlobeNewswire
Mar-21-22 07:00AM	Vaxxinity Appoints Dr. Peter Powchik to Board of Directors GlobeNewswire
Feb-11-22 09:28AM	Vaxxinitys COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern GlobeNewswire
Jan-13-22 10:53AM	Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study Zacks -9.26%
Jan-12-22 09:21AM	Vaxxinity Announces First Parkinsons Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312 GlobeNewswire +29.67%
08:10AM	Vaxxinity Shares Rise After First Patient Dosed in Parkinson's Study Investing.com
Jan-10-22 07:00AM	Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinsons Research (MJFF) to Support UB-312 Vaccine Study GlobeNewswire
Jan-04-22 07:00AM	Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors GlobeNewswire
Dec-23-21 04:45PM	Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates GlobeNewswire
Dec-07-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday InvestorPlace +24.45%
Nov-28-21 07:55AM	Vaxxinity Has a Rough Public Debut Motley Fool
Nov-18-21 04:05PM	Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Nov-16-21 12:41PM	Vaxxinity Insider Makes $240K Stock Purchase Benzinga -5.19%
Nov-11-21 04:42PM	Vaxxinity, Backblaze Shares Gain in Debuts, but 3 Other IPOs Drop Barrons.com
01:59PM	Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price MarketWatch
06:43AM	Vaxxinity to go public with $1.6 billion valuation as downsized IPO priced below the expected range MarketWatch
06:30AM	Vaxxinity Announces Pricing of Initial Public Offering GlobeNewswire

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Prime Movers Lab Fund I LP	10% Owner	Jan 23	Sale	3.35	405,217	1,358,044	8,764,372	Jan 25 05:58 PM
Prime Movers Lab Fund I LP	10% Owner	Jan 23	Sale	3.35	95,475	319,975	2,065,027	Jan 25 05:58 PM
Prime Movers Lab Fund I LP	10% Owner	Dec 02	Sale	2.57	11,121	28,561	9,169,589	Dec 05 05:31 PM
Prime Movers Lab Fund I LP	10% Owner	Dec 02	Sale	2.57	2,620	6,729	2,160,502	Dec 05 05:31 PM
Prime Movers Lab Fund I LP	10% Owner	Dec 01	Sale	2.97	270,964	805,224	9,180,710	Dec 05 05:31 PM
Prime Movers Lab Fund I LP	10% Owner	Dec 01	Sale	2.97	63,843	189,722	2,163,122	Dec 05 05:31 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 06	Sale	2.40	25,243	60,656	9,451,674	Sep 08 04:55 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 06	Sale	2.40	12,115	29,111	836,499	Sep 08 04:55 PM
Prime Movers Lab Fund I LP	10% Owner	Aug 25	Sale	2.33	22,757	53,047	9,476,917	Aug 25 06:02 PM
Prime Movers Lab Fund I LP	10% Owner	Aug 25	Sale	2.33	10,923	25,462	838,733	Aug 25 06:02 PM
Prime Movers Lab Fund I LP	10% Owner	Aug 24	Sale	2.39	83,786	199,930	9,499,674	Aug 25 06:02 PM
Prime Movers Lab Fund I LP	10% Owner	Aug 24	Sale	2.39	40,214	95,959	840,747	Aug 25 06:02 PM
Prime Movers Lab Fund I LP	10% Owner	Aug 23	Sale	2.45	33,785	82,658	9,583,460	Aug 25 06:02 PM
Prime Movers Lab Fund I LP	10% Owner	Aug 23	Sale	2.45	16,215	39,672	848,162	Aug 25 06:02 PM
Guirakhoo Farshad	(Former) Chief Scientific Off.	Aug 22	Option Exercise	0.57	2,640	1,505	68,645	Aug 29 04:45 PM
Guirakhoo Farshad	(Former) Chief Scientific Off.	Aug 15	Option Exercise	0.57	26,005	14,823	66,005	Aug 29 04:45 PM
Guirakhoo Farshad	(Former) Chief Scientific Off.	Jul 29	Option Exercise	0.57	20,000	11,400	40,000	Aug 29 04:45 PM
Reese Lou	Executive Chairman	Jun 16	Buy	1.99	100,000	199,290	51,737,344	Jun 21 04:57 PM
UNITED BIOMEDICAL INC	10% Owner	Jun 16	Buy	1.99	100,000	199,290	51,737,344	Jun 21 04:52 PM
Hu Mei Mei	See Remarks	Jun 16	Buy	1.99	100,000	199,290	51,737,344	Jun 21 04:52 PM
Prime Movers Lab Fund I LP	10% Owner	Jun 13	Sale	2.43	92,569	224,563	9,617,245	Jun 14 07:08 PM
Prime Movers Lab Fund I LP	10% Owner	Jun 13	Sale	2.43	44,431	107,785	851,152	Jun 14 07:08 PM
Prime Movers Lab Fund I LP	10% Owner	Jun 10	Sale	2.80	28,378	79,404	9,709,814	Jun 14 07:08 PM
Prime Movers Lab Fund I LP	10% Owner	Jun 10	Sale	2.80	13,622	38,116	859,345	Jun 14 07:08 PM
Reese Lou	Executive Chairman	Jun 09	Buy	2.72	10,978	29,852	51,637,344	Jun 10 06:11 PM
Hu Mei Mei	See Remarks	Jun 09	Buy	2.72	10,978	29,852	51,637,344	Jun 10 06:13 PM
UNITED BIOMEDICAL INC	10% Owner	Jun 09	Buy	2.72	10,978	29,852	51,637,344	Jun 10 06:14 PM
UNITED BIOMEDICAL INC	10% Owner	Jun 08	Buy	2.95	10,000	29,534	51,626,366	Jun 10 06:14 PM
Hu Mei Mei	See Remarks	Jun 08	Buy	2.95	10,000	29,534	51,626,366	Jun 10 06:13 PM
Reese Lou	Executive Chairman	Jun 08	Buy	2.95	10,000	29,534	51,626,366	Jun 10 06:11 PM
Guirakhoo Farshad	Chief Scientific Officer	May 03	Option Exercise	0.57	10,000	5,700	10,000	May 05 01:39 PM
Hu Mei Mei	See Remarks	Apr 27	Buy	3.58	4,807	17,222	51,616,366	Apr 28 07:19 PM
Reese Lou	Executive Chairman	Apr 27	Buy	3.58	4,807	17,222	51,616,366	Apr 28 07:25 PM
UNITED BIOMEDICAL INC	10% Owner	Apr 27	Buy	3.58	4,807	17,222	51,616,366	Apr 28 07:35 PM
UNITED BIOMEDICAL INC	10% Owner	Apr 26	Buy	3.45	18,105	62,468	51,611,559	Apr 28 07:35 PM
Reese Lou	Executive Chairman	Apr 26	Buy	3.45	18,105	62,468	51,611,559	Apr 28 07:25 PM
Hu Mei Mei	See Remarks	Apr 26	Buy	3.45	18,105	62,468	51,611,559	Apr 28 07:19 PM
Hu Mei Mei	See Remarks	Apr 25	Buy	3.37	8,038	27,073	51,593,454	Apr 27 08:47 PM
Reese Lou	Executive Chairman	Apr 25	Buy	3.37	8,038	27,073	51,593,454	Apr 27 08:40 PM
UNITED BIOMEDICAL INC	10% Owner	Apr 25	Buy	3.37	8,038	27,073	5,193,454	Apr 27 08:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience